{"id":"W2117178293","doi":"10.1358/dot.2004.40.11.872578","title":"Efalizumab: Advancing psoriasis management with a novel, targetedT-cell modulator","year":2004,"lang":"en","type":"review","venue":"Drugs of today","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Psoriasis; Medicine; Pathogenesis; Monoclonal antibody; Immunology; Clinical trial; Monoclonal; Dermatology; Antibody; Plaque psoriasis; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005817658,0.000921219,0.001243486,0.00218985,0.0002842094,0.000969286,0.0007883331,0.001359063,0.003223264],"category_scores_gemma":[0.0003302223,0.0002549634,0.000450101,0.001930578,0.0003601233,0.001314391,0.0005995078,0.00183467,0.002909655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007574672,"about_ca_system_score_gemma":0.0006887521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008749328,"about_ca_topic_score_gemma":0.001908788,"domain_scores_codex":[0.9998031,0.0000313437,0.00002493439,0.00003020775,0.00008965904,0.00002078222],"domain_scores_gemma":[0.9998778,0.00003625166,0.00002720043,0.000005238499,0.00003406948,0.00001942837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008505301,0.0001042929,0.0001260083,0.004897981,0.00004757283,0.0003750976,0.00003871334,0.0002902443,0.004205048,0.002110384,0.01671439,0.9710053],"study_design_scores_gemma":[0.00006678345,0.0001585692,0.0009542983,0.001578374,0.00005726767,0.003645249,0.00004369143,0.000161784,0.001150614,0.001359678,0.9908075,0.00001608382],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002426208,0.9978707,0.0002720747,0.0003649589,0.0001998092,0.000007343944,0.000009471062,0.00001455277,0.001018497],"genre_scores_gemma":[0.001147575,0.9964684,0.0005823078,0.0003072727,0.0002288224,0.000009984377,0.00002273289,0.000002283004,0.001230547],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003223264,"threshold_uncertainty_score":0.0107829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01323569622806394,"score_gpt":0.2490423389269608,"score_spread":0.2358066426988968,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}